Carl Gray
Expertise in
85
conditions

Dr. Carl Gray

Hematology Oncology | Hematology | Oncology
Ogden, UT 
On Staff At
Accepting New Patients
Referral may be required
Expertise in
85
conditions
Ogden, UT 

Overview

Carl Gray is a Hematologist Oncology specialist and a Hematologist practicing medicine in Ogden, Utah.

Dr. Gray is highly rated in 85 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Childhood Iron Deficiency Anemia, and Paget Disease of the Breast.

Dr. Gray is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 6 clinical trials. Dr. Gray is currently accepting new patients.

Graduate Institution

The University Of Texas Medical School At Houston

Residency

University Of Ca Davis Med Ctr

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in UT

Board Certifications

American Board Of Internal Medicine

Fellowships

University Of Ca Davis Med Ctr

Hospital Affiliations

Holy Cross Hospital-Davis
Ogden Regional Medical Center
Bear River Valley Hospital
Intermountain Health Layton Hospital
Mckay-Dee Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ogden Clinic- Ogden Ut Hematology Oncology
Ogden, UT 84405
Other Locations
Ogden Clinic Specialty Services
970 Medical Dr Ste 300, Brigham City, UT 84302
Ogden Clinic- Bountiful Ut Hematology Oncology
620 Medical Dr Ste 300, Bountiful, UT 84010
Ogden Clinic Professional Center North
4650 Harrison Blvd, Ogden, UT 84403

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Biological, Drug
Study Drugs: Dostarlimab, Niraparib
Study Phase: Phase 2
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 5 Less Clinical Trials

1 Total Publications

Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Journal: International journal of surgical oncology
Published: May 28, 2011
Similar Doctors
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology

Pediatric Bone Marrow Transplant

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (27.5 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances

Michael Pulsipher is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Pulsipher is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant. Dr. Pulsipher is board certified in American Board Of Pediatrics.

Expertise in
7
conditions
Dr. Elizabeth Raetz
Hematology | Oncology
Expertise in
7
conditions
Dr. Elizabeth Raetz
Hematology | Oncology

Pediatric Hematology-Oncology

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (27.5 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elizabeth Raetz is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Raetz is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Raetz is board certified in American Board Of Pediatrics. Dr. Raetz is currently accepting new patients.

Expertise in
12
conditions
Dr. Hassan Yaish
Hematology | Oncology
Expertise in
12
conditions
Dr. Hassan Yaish
Hematology | Oncology

Office

127 S 500 E Ste 600, 
Salt Lake City, UT 
 (27.4 miles away)
801-581-2121
Languages Spoken:
English
See accepted insurances

Hassan Yaish is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Yaish is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Pyruvate Kinase Deficiency, Hemolysis, Hereditary Spherocytosis, Anemia, and Splenectomy.

Frequently Asked Questions about Dr. Carl Gray

How do I make an appointment with Dr. Carl Gray?

You can book an appointment with Dr. Carl Gray by calling their office at 801-476-1777. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carl Gray a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carl Gray is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carl Gray specialize in?

While Dr. Carl Gray is a Hematology Oncology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Breast Cancer, and Childhood Iron Deficiency Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Carl Gray participate in research or clinical trials?

Yes. Dr. Carl Gray has published 1 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Carl Gray's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carl Gray accept my insurance?

Dr. Carl Gray accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-476-1777 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gray's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 67 Advanced Conditions
    View All 161 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile